-+ 0.00%
-+ 0.00%
-+ 0.00%

MoonLake submits FDA BLA for sonelokimab in hidradenitis suppurativa

PUBT·09/30/2026 20:16:31
Listen to the news
MoonLake submits FDA BLA for sonelokimab in hidradenitis suppurativa
  • MoonLake Immunotherapeutics filed a BLA with the FDA on Sept. 30, 2026 for sonelokimab in moderate-to-severe hidradenitis suppurativa.
  • Application seeks use in adults, pediatric patients aged 12 years or older.
  • FDA acceptance decision expected within about 60 days; review timeline expected within about 74 days.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-105240), on September 30, 2026, and is solely responsible for the information contained therein.